|
|
|
|
Remedies for Safer Drugs
Drug Safety New solutions to seek signals, organize data, train interpreters, expedite reporting, and find better biomarkers. By Deborah Borfitz January 10, 2012 | Pharmacovigilance experts have an abundance
|
|
What is (Quantitative) Systems Pharmacology?
By John Russell January 10, 2012 | The Russell Transcript | Just a few days apart in the middle of October, Harvard Medical School (HMS) announced a broad initiative in systems pharmacology and NIH released a like minded white paper,
|
|
The Pharmaceutical Safety Data Problem
By Ernie Bush January 10, 2012 | Bush Doctrine | I doubt most people fully appreciate the size and scope of the pharmaceutical safety informatics space. I consider myself an avowed information systems advocate with decades of pharma R&D experience,
|
|
NuMedii’s New Way to ‘De-Risk’ Drug Repositioning Work
Stanford University spin off relies on database to identify new drug uses. By Deborah Borfitz November 15, 2011 | A newly minted biotechnology company is offering to match the molecular genomic activity of previously approved medicines to that of known
|
|
Recent Sequencing Plans by the Numbers
Xconomy | What do 10,000 people with autism, 50,000 people in some remote islands in the North Atlantic, and 1,000 healthy old folks in southern California have in common?
|
|
New iReport Product Quickly Processes 'Omics Data
Bio-IT World | Ingenuity Systems has just announced its iReport product for quickly making sense of 'omics data and will offer free, early access to the first 5,000 researchers to sign up by October 31.
|
|
Predictive Science Center in Russia
AstraZeneca to contribute to development of bioinformatics and predictive medicine in Russia. By Eugene Gerden September 27, 2011 | AstraZeneca, the world’s seventh largest pharmaceutical company, has announced its plans to establish a predictive science center for bioinformatics and predictive
|
|
Reevaluating the Role of the Research Librarian
By Rya Ben Shir and Alexander Feng September 27, 2011 | If your image of a research librarian is the soft spoken, bespectacled woman politely shushing you when you’re talking in the library, that outdated perception couldn’t be further from
|
|
Powering Preventative Medicine
DNA Electronics is building the foundations for semiconductor sequencing. By Kevin Davies September 27, 2011 | DNA Electronics certainly sounds like the quintessential bio IT company, but this London firm is quietly making waves in the field of next generation
|
|
Big Pharma’s Last Refuge
By Bill Frezza September 27, 2011 | The Skeptical Outsider | In the previous issue of Bio•IT World (July August 2011), my fellow columnist Ernie Bush posed the question, what are the limits to collaboration among pharmaceutical companies? This same
|
Turning Genomics Data into Practical Insight With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can: - Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines.
- Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image).
Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands.
New Complimentary Market Survey… Collaborations and Communications Within Drug Discovery Research This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns. An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
Scientific Software Engineer
Boston MA
$70,000 to $95,000
Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET.
Apply at http://jobs.tessella.com
Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes. As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers. This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions. It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply
Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules. It is therefore suitable for use in a variety of markets including scientific research and clinical applications. As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team. The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market. This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company. Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial leadership, who wish to apply a fresh approach to existing markets. Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries. We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products. Click to Apply
|
|
|